Detalhe da pesquisa
1.
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2.
Proc Natl Acad Sci U S A;
121(6): e2317756121, 2024 Feb 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38300868
2.
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations.
Cancer Discov;
13(9): 2012-2031, 2023 09 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37270847
3.
Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence Time.
ACS Med Chem Lett;
11(6): 1205-1212, 2020 Jun 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32551002